Seminars in Thrombosis & Hemostasis 2010: Impact Factor and Highest-Cited Articles from 2008 to 2009

As I have noted several times before, the end of a year is a good time to reflect on the past. We say farewell to the end of another year with Seminars in Thrombosis & Hemostasis, the third year with a reshaped and expanded editorial team, including yours truly as Editor in Chief. We have already mentioned many times in the past the long history that has led to the editorial restructuring, including the passing away of the journal's founding Editor in Chief, Dr. Eberhard F, Mammen, in 2008.[1] [2] [3] [4] [5] [6] [7] [8] [9]

I would at this time very much like to thank our entire editorial team, our guest editors, and all the authors who have contributed articles to this journal over the past year. I would also like to thank all members of the Thieme team, whose contribution to the success or otherwise of this journal is critical, but which goes generally unrecognized by the readership. In particular, I would like to acknowledge the invaluable assistance of Xenia Golovchenko, the Production Editor for Thieme Medical Publishers, who is ultimately responsible for bringing out every issue of Seminars in Thrombosis & Hemostasis to press.

I would also take this time to reflect on our journal's impact factor, which for 2010 was 4.169 (see Fig. [1]). This reflects a substantial rise from our lower impact factor for 2009, which we previously attributed to the delay in publication of many issues in 2007 and 2008, in turn reflecting the difficult period related to the protracted illness and eventual passing away of the then editor in chief. Notably, the impact factor for 2010, being above 4, represents a first for Seminars in Thrombosis & Hemostasis. We take this to mean that this journal is progressing laudably.

Figure 1 Impact Factor for Seminars in Thrombosis & Hemostasis for the period 2003 to 2010.

I have previously highlighted,[10] [11] and would continue to assert that the impact factor is not the only marker of journal quality we should consider, given the existence of other biometric markers and the limitations of any individual marker (including the impact factor) as an indicator of journal quality. Nevertheless, the top 48 list of 2010-cited (2008/2009 published) articles from this journal is given in Table [1].[11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] These articles can be identified as those most contributing to the 2010 impact factor, and each were cited six or more times in 2010. The top 13 on the list were cited between 10 and 18 times each in 2010.

Table 1 Top 48 Listing of 2010-Cited Articles from Seminars in Thrombosis & Hemostasis and Published in 2008 or 2009a Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, Palomo I, Harris EN, Meroni PL. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008 Apr;34(3):236–250. Favaloro EJ, Lippi G, Adcock DM. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis? Semin Thromb Hemost 2008 Oct;34(7):612–634. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009 Mar;35(2):189–203. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008 Nov;34(8):709–733. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009 Apr;35(3):313–324. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 2008 Nov;34(8):747–761. McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009 Mar;35(2):168–180. Favaloro EJ, Wong RC. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost 2008 Jun;34(4):389–410. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008 Feb;34(1):39–57. Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008 Feb;34(1):58–73. Franchini M, Franchi M, Bergamini V, Salvagno GL, Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost 2008 Feb;34(1):104–112. Harrison P, Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin Thromb Hemost 2009 Mar;35(2):150–157. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 2008 Jul;34(5):459–468. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009 Mar;35(2):158–167. Enjeti AK, Lincz LF, Seldon M. Microparticles in health and disease. Semin Thromb Hemost 2008 Oct;34(7):683–691. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009 Jul;35(5):515–524. Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009 Nov;35(8):723–734. Harenberg J. Development of new anticoagulants: present and future. Semin Thromb Hemost 2008 Nov;34(8):779–793. Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008 Oct;34(7):604–611. Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009 Jun;35(4):400–406. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009 Apr;35(3):277–287. de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009 Jun;35(4):356–366. Falanga A, Barbui T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 2008 Mar;34(2):204–210. Favaloro EJ. Internal quality control and external quality assurance of platelet function tests. Semin Thromb Hemost 2009 Mar;35(2):139–149. Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. Semin Thromb Hemost 2008 Feb;34(1):7–25. Franchini M, Mannucci PM. Von Willebrand factor: another janus-faced hemostasis protein. Semin Thromb Hemost 2008 Oct;34(7):663–669. Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost 2009 Nov;35(8):760–768. Levi M, Schouten M, van der Poll T. Sepsis, coagulation, and antithrombin: old lessons and new insights. Semin Thromb Hemost 2008 Nov;34(8):742–746. Lippi G, Favaloro EJ, Franchini M, Guidi GC. Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost 2009 Feb;35(1):9–22. Pai M, Hayward CP. Diagnostic assessment of platelet disorders: what are the challenges to standardization? Semin Thromb Hemost 2009 Mar;35(2):131–138. Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2008 Feb;34(1):86–96. Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008 Mar;34(2):147–153. Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost 2008 Apr;34(3):267–273. Zwicker JI. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008 Mar;34(2):195–198. Berntorp E, Salvagno GL. Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost 2008 Oct;34(7):670–682. Dempfle CE, Borggrefe M. Point of care coagulation tests in critically ill patients. Semin Thromb Hemost 2008 Jul;34(5):445–450. Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009 Nov;35(8):794–805. Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost 2008 Feb;34(1):113–127. Favaloro EJ. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost 2009 Feb;35(1):60–75. Hunt BJ. Pediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2008 Apr;34(3):274–281. Isbister GK. Procoagulant snake toxins: laboratory studies, diagnosis, and understanding snakebite coagulopathy. Semin Thromb Hemost 2009 Feb;35(1):93–103. Israels SJ. Diagnostic evaluation of platelet function disorders in neonates and children: an update. Semin Thromb Hemost 2009 Mar;35(2):181–188. Kitchen S, Jennings I, Preston FE, Kitchen DP, Woods TA, Walker ID. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. Semin Thromb Hemost 2009 Nov;35(8):778–785. Levi M, Löwenberg EC. Thrombocytopenia in critically ill patients. Semin Thromb Hemost 2008 Jul;34(5):417–424. Lippi G, Maffulli N. Biological influence of physical exercise on hemostasis. Semin Thromb Hemost 2009 Apr;35(3):269–276. Nurden AT, Fiore M, Pillois X, Nurden P. Genetic testing in the diagnostic evaluation of inherited platelet disorders. Semin Thromb Hemost 2009 Mar;35(2):204–212. Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost 2008 Mar;34(2):154–160. Prisco D, Grifoni E. The role of D-dimer testing in patients with suspected venous thromboembolism. Semin Thromb Hemost 2009 Feb;35(1):50–59. aEach of these articles were cited between 6 and 18 times in 2010. These would therefore be identified as most contributing to the 2010 impact factor for Seminars in Thrombosis & Hemostasis. The articles are listed in decreasing order of citations or alphabetically for those articles having the same number of citations.

For those of you interested, this list can be compared with the recently published top 50 downloaded articles from Seminars in Thrombosis & Hemostasis from 2009 to 2010, the basis of the Eberhard Mammen “Most Popular” awards.[60]

Finally, a short note to confirm that the editorial team will continue to develop plans for the future content of this journal, and we are confident that we will be able to continue to bring to you—the reader—the high quality you have come to expect in Seminars in Thrombosis & Hemostasis. Currently confirmed topics for issues that we plan to publish over the next 12 or so months are listed in Table [2]. At the same time, we recognize the need to retain some flexibility in our plans, and to potentially add additional material of current interest and controversy as the need arises.

Table 2 Planned Topics for Future Issues of Seminars in Thrombosis & Hemostasis Hot Topics  • Prohemostatic treatments according to clinical setting  • Key molecules in thrombosis and hemostasis  • Laboratory and clinical identification and treatment of bleeding disorders  • Thrombotic and hemorrhagic syndromes associated with autoimmunity and infection  • Quality in thrombosis and hemostasis  • Antiphospholipid syndrome  • Clinical approaches to common bleeding and thrombotic disorders  • Adverse drug effects on thrombosis and hemostasis  • Back to basics: preanalytical, analytical, and postanalytical variables in hemostasis testing

We look forward to another interesting year of reading in 2012!

REFERENCES

• 1 Schiff D, Burgess T. Editorial.  Semin Thromb Hemost. 2004;  30 601-602
• 2 Favaloro E J. Editorial. Welcome to Seminars in Thrombosis and Hemostasis – 2008!.  Semin Thromb Hemost. 2008;  34 1-2
• 3 Schiff D. Eulogy. Eberhard Mammen, M.D. 1930–2008.  Semin Thromb Hemost. 2008;  34 305
• 4 Favaloro E J. Editorial.  Semin Thromb Hemost. 2008;  34 307
• 5 Favaloro E J. Editorial. Welcome to a special issue of Seminars in Thrombosis and Hemostasis—the closing issue for 2008.  Semin Thromb Hemost. 2008;  34 693-696
• 6 Prasad A, Kwaan H C. In memoriam: a tribute to Eberhard F Mammen, M.D. (1930–2008).  Semin Thromb Hemost. 2008;  34 693-696
• 7 Favaloro E J. A tribute to Eberhard F Mammen, M.D. (1930-2008).  Semin Thromb Hemost. 2008;  34 (8) 703-707
• 8 Favaloro E J. Editorial. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009.  Semin Thromb Hemost. 2009;  35 1-2
• 9 Favaloro E J. Editorial. Farewell to 2010!.  Semin Thromb Hemost. 2010;  36 797-802
• 10 Favaloro E J. The journal impact factor: don't expect its demise any time soon.  Clin Chem Lab Med. 2009;  47 (11) 1319-1324
• 11 Favaloro E J. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story.  Semin Thromb Hemost. 2008;  34 (1) 7-25
• 12 Pierangeli S S, Chen P P, Raschi E et al.. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.  Semin Thromb Hemost. 2008;  34 (3) 236-250
• 13 Favaloro E J, Lippi G, Adcock D M. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis?.  Semin Thromb Hemost. 2008;  34 (7) 612-634
• 14 Althaus K, Greinacher A. MYH9-related platelet disorders.  Semin Thromb Hemost. 2009;  35 (2) 189-203
• 15 Favaloro E J. Clinical utility of the PFA-100.  Semin Thromb Hemost. 2008;  34 (8) 709-733
• 16 Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.  Semin Thromb Hemost. 2009;  35 (3) 313-324
• 17 Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over.  Semin Thromb Hemost. 2008;  34 (8) 747-761
• 18 McGlasson D L, Fritsma G A. Whole blood platelet aggregometry and platelet function testing.  Semin Thromb Hemost. 2009;  35 (2) 168-180
• 19 Favaloro E J, Wong R C. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions.  Semin Thromb Hemost. 2008;  34 (4) 389-410
• 20 Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.  Semin Thromb Hemost. 2008;  34 (1) 39-57
• 21 Fareed J, Hoppensteadt D A, Fareed D et al.. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.  Semin Thromb Hemost. 2008;  34 (1) 58-73
• 22 Franchini M, Franchi M, Bergamini V, Salvagno G L, Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage.  Semin Thromb Hemost. 2008;  34 (1) 104-112
• 23 Harrison P, Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing.  Semin Thromb Hemost. 2009;  35 (2) 150-157
• 24 Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients.  Semin Thromb Hemost. 2008;  34 (5) 459-468
• 25 Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function.  Semin Thromb Hemost. 2009;  35 (2) 158-167
• 26 Enjeti A K, Lincz L F, Seldon M. Microparticles in health and disease.  Semin Thromb Hemost. 2008;  34 (7) 683-691
• 27 Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation.  Semin Thromb Hemost. 2009;  35 (5) 515-524
• 28 Gouw S C, van den Berg H M. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.  Semin Thromb Hemost. 2009;  35 (8) 723-734
• 29 Harenberg J. Development of new anticoagulants: present and future.  Semin Thromb Hemost. 2008;  34 (8) 779-793
• 30 Lippi G, Favaloro E J. Activated partial thromboplastin time: new tricks for an old dogma.  Semin Thromb Hemost. 2008;  34 (7) 604-611
• 31 Mariani G, Bernardi F. Factor VII deficiency.  Semin Thromb Hemost. 2009;  35 (4) 400-406
• 32 Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome.  Semin Thromb Hemost. 2009;  35 (3) 277-287
• 33 de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders.  Semin Thromb Hemost. 2009;  35 (4) 356-366
• 34 Falanga A, Barbui T, Rickles F R. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies.  Semin Thromb Hemost. 2008;  34 (2) 204-210
• 35 Favaloro E J. Internal quality control and external quality assurance of platelet function tests.  Semin Thromb Hemost. 2009;  35 (2) 139-149
• 36 Favaloro E J. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story.  Semin Thromb Hemost. 2008;  34 (1) 7-25
• 37 Franchini M, Mannucci P M. Von Willebrand factor: another janus-faced hemostasis protein.  Semin Thromb Hemost. 2008;  34 (7) 663-669
• 38 Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center.  Semin Thromb Hemost. 2009;  35 (8) 760-768
• 39 Levi M, Schouten M, van der Poll T. Sepsis, coagulation, and antithrombin: old lessons and new insights.  Semin Thromb Hemost. 2008;  34 (8) 742-746
• 40 Lippi G, Favaloro E J, Franchini M, Guidi G C. Milestones and perspectives in coagulation and hemostasis.  Semin Thromb Hemost. 2009;  35 (1) 9-22
• 41 Pai M, Hayward C P. Diagnostic assessment of platelet disorders: what are the challenges to standardization?.  Semin Thromb Hemost. 2009;  35 (2) 131-138
• 42 Prechel M, Walenga J M. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.  Semin Thromb Hemost. 2008;  34 (1) 86-96
• 43 Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer.  Semin Thromb Hemost. 2008;  34 (2) 147-153
• 44 Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment.  Semin Thromb Hemost. 2008;  34 (3) 267-273
• 45 Zwicker J I. Tissue factor-bearing microparticles and cancer.  Semin Thromb Hemost. 2008;  34 (2) 195-198
• 46 Berntorp E, Salvagno G L. Standardization and clinical utility of thrombin-generation assays.  Semin Thromb Hemost. 2008;  34 (7) 670-682
• 47 Dempfle C E, Borggrefe M. Point of care coagulation tests in critically ill patients.  Semin Thromb Hemost. 2008;  34 (5) 445-450
• 48 Favaloro E J, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors.  Semin Thromb Hemost. 2009;  35 (8) 794-805
• 49 Favaloro E J. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?.  Semin Thromb Hemost. 2008;  34 (1) 113-127
• 50 Favaloro E J. Toward a new paradigm for the identification and functional characterization of von Willebrand disease.  Semin Thromb Hemost. 2009;  35 (1) 60-75
• 51 Hunt B J. Pediatric antiphospholipid antibodies and antiphospholipid syndrome.  Semin Thromb Hemost. 2008;  34 (3) 274-281
• 52 Isbister G K. Procoagulant snake toxins: laboratory studies, diagnosis, and understanding snakebite coagulopathy.  Semin Thromb Hemost. 2009;  35 (1) 93-103
• 53 Israels S J. Diagnostic evaluation of platelet function disorders in neonates and children: an update.  Semin Thromb Hemost. 2009;  35 (2) 181-188
• 54 Kitchen S, Jennings I, Preston F E, Kitchen D P, Woods T A, Walker I D. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation.  Semin Thromb Hemost. 2009;  35 (8) 778-785
• 55 Levi M, Löwenberg E C. Thrombocytopenia in critically ill patients.  Semin Thromb Hemost. 2008;  34 (5) 417-424
• 56 Lippi G, Maffulli N. Biological influence of physical exercise on hemostasis.  Semin Thromb Hemost. 2009;  35 (3) 269-276
• 57 Nurden A T, Fiore M, Pillois X, Nurden P. Genetic testing in the diagnostic evaluation of inherited platelet disorders.  Semin Thromb Hemost. 2009;  35 (2) 204-212
• 58 Palumbo J S. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination.  Semin Thromb Hemost. 2008;  34 (2) 154-160
• 59 Prisco D, Grifoni E. The role of D-dimer testing in patients with suspected venous thromboembolism.  Semin Thromb Hemost. 2009;  35 (1) 50-59
• 60 Favaloro E J. Editorial. 2011 Eberhard F. Mammen Award announcements.  Semin Thromb Hemost. 2011;  37 431-439